124 related articles for article (PubMed ID: 8790560)
1. Clinical predictors of response to recombinant interferon-alpha treatment in patients with chronic non-A, non-B hepatitis (hepatitis C). The Hepatitis Interventional Therapy Group.
Davis GL; Lindsay K; Albrecht J; Bodenheimer HC; Balart LA; Perrillo RP; Dienstag JL; Tamburro C; Schiff ER; Carey W
J Viral Hepat; 1994; 1(1):55-63. PubMed ID: 8790560
[TBL] [Abstract][Full Text] [Related]
2. Re-treatment of interferon-resistant patients with chronic hepatitis C with interferon-alpha.
Bresci G; Parisi G; Banti S; Capzia A
J Viral Hepat; 1995; 2(3):155-8. PubMed ID: 7493311
[TBL] [Abstract][Full Text] [Related]
3. Dose increase augments response rate to interferon-alpha in chronic hepatitis C.
Ferenci P; Stauber R; Propst A; Fiedler R; Müller C; Gschwantler M; Schütze K; Datz C; Judmaier G; Vogel W; Krejs GJ; Gangl A
Dig Dis Sci; 1996 Dec; 41(12 Suppl):103S-108S. PubMed ID: 9011466
[TBL] [Abstract][Full Text] [Related]
4. Treatment of chronic hepatitis C with cirrhosis with recombinant human granulocyte colony-stimulating factor plus recombinant interferon-alpha.
Pardo M; Castillo I; Navas S; Carreño V
J Med Virol; 1995 Apr; 45(4):439-44. PubMed ID: 7545214
[TBL] [Abstract][Full Text] [Related]
5. [Treatment with interferon alfa-2b in patients with chronic hepatitis caused by hepatitis C virus: predictive factors for the response, relapse and early development to cirrhosis after treatment].
Pérez Roldán F; De Diego A; Casado M; Matilla A; Bañares R; García-Durán F; Salcedo M; Cos E; Clemente G
Rev Esp Enferm Dig; 1996 Sep; 88(9):609-15. PubMed ID: 8962775
[TBL] [Abstract][Full Text] [Related]
6. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group.
Lindsay KL; Davis GL; Schiff ER; Bodenheimer HC; Balart LA; Dienstag JL; Perrillo RP; Tamburro CH; Goff JS; Everson GT; Silva M; Katkov WN; Goodman Z; Lau JY; Maertens G; Gogate J; Sanghvi B; Albrecht J
Hepatology; 1996 Nov; 24(5):1034-40. PubMed ID: 8903371
[TBL] [Abstract][Full Text] [Related]
7. A randomized controlled trial of recombinant interferon-alpha in chronic hepatitis C in hemophiliacs.
Makris M; Preston FE; Triger DR; Underwood JC; Westlake L; Adelman MI
Blood; 1991 Oct; 78(7):1672-7. PubMed ID: 1912556
[TBL] [Abstract][Full Text] [Related]
8. Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C: a multi-center, randomized, double-blind, placebo-controlled trial. Leich Study Group.
Niederau C; Strohmeyer G; Heintges T; Peter K; Göpfert E
Hepatogastroenterology; 1998; 45(21):797-804. PubMed ID: 9684137
[TBL] [Abstract][Full Text] [Related]
9. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
10. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients.
Rostaing L; Izopet J; Baron E; Duffaut M; Puel J; Durand D
Transplantation; 1995 May; 59(10):1426-31. PubMed ID: 7770930
[TBL] [Abstract][Full Text] [Related]
12. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
Nadeem A; Hussain MM; Aslam M; Hussain T; Butt IF; Ali Khan S; Asad A
J Ayub Med Coll Abbottabad; 2009; 21(2):103-6. PubMed ID: 20524482
[TBL] [Abstract][Full Text] [Related]
13. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
Keeffe EB; Hollinger FB
Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
[TBL] [Abstract][Full Text] [Related]
14. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
Iino S; Hino K; Kuroki T; Suzuki H; Yamamoto S
Dig Dis Sci; 1993 Apr; 38(4):612-8. PubMed ID: 8384980
[TBL] [Abstract][Full Text] [Related]
15. Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc).
Payen JL; Izopet J; Galindo-Migeot V; Lauwers-Cances V; Zarski JP; Seigneurin JM; Dussaix E; Voigt JJ; Selves J; Barange K; Puel J; Pascal JP
Hepatology; 1998 Dec; 28(6):1680-6. PubMed ID: 9828235
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover.
Zeuzem S; Schmidt JM; Lee JH; von Wagner M; Teuber G; Roth WK
Hepatology; 1998 Jul; 28(1):245-52. PubMed ID: 9657119
[TBL] [Abstract][Full Text] [Related]
17. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group.
Tong MJ; Reddy KR; Lee WM; Pockros PJ; Hoefs JC; Keeffe EB; Hollinger FB; Hathcote EJ; White H; Foust RT; Jensen DM; Krawitt EL; Fromm H; Black M; Blatt LM; Klein M; Lubina J
Hepatology; 1997 Sep; 26(3):747-54. PubMed ID: 9303508
[TBL] [Abstract][Full Text] [Related]
18. Histological outcome in patients with chronic hepatitis C given a 60-week interferon alfa-2b treatment course.
Reichard O; Glaumann H; Norkrans G; Wejstål R; Fryden A; Schvarcz R; Weiland O
Liver; 1994 Aug; 14(4):169-74. PubMed ID: 7526108
[TBL] [Abstract][Full Text] [Related]
19. Randomized, double-blind, placebo-controlled trial of eight-week course of recombinant alpha-interferon for chronic non-A, non-B hepatitis.
Omata M; Ito Y; Yokosuka O; Imazeki F; Tagawa M; Takano S; Hosoda K; Tada M; Ohto M; Ito K
Dig Dis Sci; 1991 Sep; 36(9):1217-22. PubMed ID: 1654240
[TBL] [Abstract][Full Text] [Related]
20. Behavior of soluble HLA class I antigens in patients with chronic hepatitis C during interferon therapy: an early predictor marker of response?
Puppo F; Picciotto A; Brenci S; Varagona G; Scudeletti M; Ghio M; Balestra V; Celle G; Indiveri F
J Clin Immunol; 1995 Jul; 15(4):179-84. PubMed ID: 7593464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
